Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Trial Profile

Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Jun 2009 Planned end date changed from 1 Dec 2010 to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top